Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.92 USD | +0.80% | +6.02% | -14.67% |
05-01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 | |
04-30 | (USNA) USANA HEALTH SCIENCES Expects Fiscal Year 2024 Revenue Range $850M - $920M | MT |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The stock, which is currently worth 2024 to 0.55 times its sales, is clearly overvalued in comparison with peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.67% | 876M | C+ | ||
+13.21% | 8.15B | D+ | ||
-0.47% | 7.27B | C- | ||
+12.30% | 6.65B | - | ||
-6.99% | 3.72B | D | ||
-7.61% | 3.67B | B- | ||
-4.78% | 1.31B | - | - | |
+12.61% | 972M | - | ||
-38.34% | 866M | B+ | ||
-17.22% | 786M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- USNA Stock
- Ratings USANA Health Sciences, Inc.